IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) has announced that on September 26, 2024, its Compensation Committee granted non-qualified stock options to a newly hired employee. The options allow for the purchase of 140,000 shares of the company's common stock under the 2023 Employment Inducement Incentive Award Plan. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for employment.
The stock options have an exercise price of $30.50 per share, matching the closing price of IDEAYA's common stock on the grant date. They have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) ha annunciato che il 26 settembre 2024, il suo Comitato per la Compensazione ha concesso opzioni su azioni non qualificate a un nuovo dipendente assunto. Le opzioni consentono l'acquisto di 140.000 azioni delle azioni ordinarie dell'azienda nell'ambito del Piano di Incentivazione per l'Occupazione del 2023. Questa concessione è conforme alla Regola di Listing del Nasdaq 5635(c)(4) e funge da incentivo per l'assunzione.
Le opzioni azionarie hanno un prezzo di esercizio di $30.50 per azione, corrispondente al prezzo di chiusura delle azioni ordinarie di IDEAYA alla data di concessione. Hanno un termine di 10 anni e si matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente nei successivi tre anni, soggetto a ulteriore impiego.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) ha anunciado que el 26 de septiembre de 2024, su Comité de Compensación otorgó opciones sobre acciones no calificadas a un nuevo empleado. Las opciones permiten la compra de 140,000 acciones de las acciones comunes de la empresa en virtud del Plan de Incentivo para el Empleo de 2023. Esta concesión se realiza de acuerdo con la Regla de Cotización del Nasdaq 5635(c)(4) y sirve como un incentivo para el empleo.
Las opciones de acciones tienen un precio de ejercicio de $30.50 por acción, correspondiente al precio de cierre de las acciones comunes de IDEAYA en la fecha de la concesión. Tienen un plazo de 10 años y se adquirirán en un período de cuatro años, con el 25% adquiriéndose después de un año y el 75% restante adquiriéndose mensualmente durante los tres años siguientes, sujeto a la continuación del empleo.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)는 2024년 9월 26일 보상위원회가 신규 고용인에게 비자격 주식 옵션을 부여했다고 발표했습니다. 이 옵션은 2023년 고용 유도 인센티브 상여 계획에 따라 회사의 보통주 140,000주를 구매할 수 있는 권리를 제공합니다. 이 부여는 Nasdaq 목록 규칙 5635(c)(4)에 따라 이루어지며 고용 유인을 위한 것입니다.
주식 옵션의 행사 가격은 주당 $30.50이며, 이는 부여일 당시 IDEAYA 보통주의 종가와 일치합니다. 이 옵션은 10년의 기간을 가지며, 4년에 걸쳐 소멸됩니다. 1년 후 25%가 소멸되고, 이후 3년 동안 매달 나머지 75%가 소멸되며, 이는 지속적인 고용에 따라 달라집니다.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) a annoncé que le 26 septembre 2024, son Comité de Rémunération a accordé des options d'achat d'actions non qualifiées à un nouvel employé. Les options permettent l'achat de 140 000 actions des actions ordinaires de l'entreprise dans le cadre du Plan d'Incitation à l'Emploi de 2023. Cette attribution est conforme à la Règle de Cotation Nasdaq 5635(c)(4) et sert d'incitation à l'emploi.
Les options d'achat d'actions ont un prix d'exercice de 30,50 $ par action, correspondant au prix de clôture des actions ordinaires d'IDEAYA à la date d'octroi. Elles ont une durée de 10 ans et se débloquent sur quatre ans, avec 25 % se débloquant après un an et les 75 % restants se débloquant mensuellement au cours des trois années suivantes, sous réserve d'un emploi continu.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) gab bekannt, dass am 26. September 2024 das Vergütungskomitee nicht qualifizierte Aktienoptionen an einen neu eingestellten Mitarbeiter vergeben hat. Die Optionen erlauben den Kauf von 140.000 Aktien der Stammaktien des Unternehmens im Rahmen des 2023 Employment Inducement Incentive Award Plans. Diese Vergabe erfolgt gemäß Nasdaq Listing Rule 5635(c)(4) und dient als Anreiz für eine Anstellung.
Die Aktienoptionen haben einen Ausübungspreis von $30,50 pro Aktie, der dem Schlusskurs der Stammaktien von IDEAYA am Vergabetag entspricht. Sie haben eine Laufzeit von 10 Jahren und verfallen über vier Jahre, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über die folgenden drei Jahre ab einem fortdauernden Beschäftigungsverhältnis verfallen.
- Attraction of new talent through stock option grants
- Alignment of employee interests with company performance through equity-based compensation
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302260793.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
How many shares of IDEAYA Biosciences (IDYA) stock options were granted on September 26, 2024?
What is the exercise price of the IDYA stock options granted on September 26, 2024?
What is the vesting schedule for the IDYA stock options granted on September 26, 2024?
Under which plan were the IDYA stock options granted on September 26, 2024?
